newsfilter
← Latest News
GlobeNewswire·

Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control